According to Zacks, “Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company’s lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals Inc., formerly known as Flex Pharma Inc., is based in Houston, Texas. “
Separately, HC Wainwright dropped their price objective on shares of Salarius Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, March 11th.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. During the same period in the previous year, the company posted ($0.10) earnings per share. As a group, equities analysts predict that Salarius Pharmaceuticals will post -0.39 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in Salarius Pharmaceuticals by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 390,115 shares of the company’s stock valued at $193,000 after buying an additional 34,001 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Salarius Pharmaceuticals in the 4th quarter valued at about $89,000. Two Sigma Advisers LP purchased a new position in Salarius Pharmaceuticals in the 3rd quarter valued at about $114,000. Millennium Management LLC boosted its position in Salarius Pharmaceuticals by 77.6% in the 3rd quarter. Millennium Management LLC now owns 59,480 shares of the company’s stock valued at $61,000 after buying an additional 25,992 shares during the last quarter. Finally, Morgan Stanley boosted its position in Salarius Pharmaceuticals by 54.8% in the 3rd quarter. Morgan Stanley now owns 759,772 shares of the company’s stock valued at $775,000 after buying an additional 268,970 shares during the last quarter. 14.75% of the stock is owned by institutional investors.
Salarius Pharmaceuticals Company Profile (Get Rating)
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma.
- Get a free copy of the StockNews.com research report on Salarius Pharmaceuticals (SLRX)
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.